



Contents lists available at ScienceDirect

Biochimica et Biophysica Acta

journal homepage: www.elsevier.com/locate/bbamem

Effects of positively charged arginine residues on membrane pore forming activity of Rev–NIS peptide in bacterial cells

Juneyoung Lee, Hyemin Choi, Jaeyong Cho, Dong Gun Lee*

School of Life Sciences and Biotechnology, College of Natural Sciences, Kyungpook National University, Daehak-ro 80, Buk-gu, Daegu 702-701, Republic of Korea

ARTICLE INFO

Article history:

Received 22 March 2011

Received in revised form 23 June 2011

Accepted 27 June 2011

Available online 6 July 2011

Keywords:

HIV-1

Rev protein

Rev–NIS

Analog

Antibacterial peptide

ABSTRACT

Here, we investigated antibacterial effects of Rev–NIS and suggested the role of positively charged amino acids on membrane pore forming activity of the peptide in bacterial cells, by synthesizing two analogs, Anal R and Anal S. Based on the amphipathic property of Rev–NIS, Anal R and Anal S were designed by substituting E¹ and L³ to R and L³ to S, respectively. The circular dichroism (CD) spectroscopy showed that Anal R and Anal S have the same conformation of Rev–NIS, with a significant fraction of helical structure. In succession, the antibacterial susceptibility testing showed that Rev–NIS and its analogs possessed significant activities (Anal R > Rev–NIS > Anal S), without hemolytic effects, against bacterial pathogens including antibiotics-resistant strains. Moreover, the membrane studies, 3,3'-dipropylthiadicarbocyanine iodide (diSC₃₅) staining and FITC-dextran (FD) leakage assay demonstrated that the analogs as well as Rev–NIS acted on the bacterial membranes and potentially made pores, with the hydrodynamic radius between 1.4 nm and 2.3 nm. Especially, Anal R made larger pores than other peptides, with the radius between 2.3 nm and 3.3 nm. These results also corresponded to the result of antibacterial susceptibility testing. In summary, this study indicates that the two arginine residues are more influential than the hydrophobicity or the helicity, regarding the molecular activity of the peptide, and finally suggests that Anal R peptide may be applied to novel antibacterial agents.

© 2011 Elsevier B.V. All rights reserved.

1. Introduction

Recently, due to the emergence of organisms possessing resistance to several antibiotics [1,2], a variety of diseases are becoming increasingly difficult to treat, including microorganisms responsible for infections in hospitalized patients, food-borne pathogens, and sexually transmitted pathogens, some of which are known to be resistant to most antimicrobial drugs [3–5]. The clinical impact of the above noted resistance is regarded as immense, characterized by increased cost, morbidity, or mortality [6,7]. Therefore, the increasing resistance against various commonly used antibiotic agents requires immediate actions, continuous studies and the eventual suggestion of novel bactericidal and fungicidal agents [8,9]. Although the search for novel naturally occurring antimicrobial molecules such as antimicrobial peptides (AMPs) has focused on the molecules isolated from plants or animals [10], actually, there is no limitation with respect to

the sources for the selection of AMPs. Most AMPs can interact, permeate and physically disrupt the cell plasma membrane, causing damages that are hard to repair and sometimes fatal, in contrast to conventionally used antibiotics that are targeting specific intracellular enzymes or DNA. Conclusively, resistance may occur with lower probability [11].

HIV-1 encodes the regulatory protein Rev constantly shuttling between the nucleus and the cytoplasm in the host cells. This protein is concerned in the control of a signal-mediated active import and export system of HIV-1, and the function of NIS region is especially critical [12–15]. If the NIS does not carry out its role, Rev may migrate back through the nuclear pore against the well-controlled nucleocytoplasmic shuttling to conduct its own role in each compartment. In the whole sequence of NIS, residues 11–20 (Rev–NIS, ELLKAVRLIK) are composed of the conserved hydrophilic motif forming an amphipathic helix. This helical motif was regarded to be critical with respect to the function of NIS and Rev itself [16]. Previously, we found that Rev–NIS exerted antifungal activities by disrupting fungal membranes of *Candida albicans* and this result suggested a therapeutic potential as new antifungal agents [17]. In this study, first, we investigated the antibacterial activity of Rev–NIS. Thereafter, we designed and synthesized two analogs, Anal R and Anal S, to investigate the effect of positively charged amino acids regarding the antibacterial activity of the peptides. Concretely, Anal R and Anal S were designed by substituting the specific amino acids, Glu¹ and Leu³ to Arg (Anal R) and Leu³ to Ser (Anal S), respectively.

Abbreviations: CD, circular dichroism; diSC₃₅, 3,3'-dipropylthiadicarbocyanine iodide; FITC, fluorescein isothiocyanate; FD, FITC-dextran; AMP, antimicrobial peptide; NIS, nuclear entry inhibitory signal; TFE, 2,2,2-trifluoroethanol; SDS, sodium dodecyl sulfate; MIC, minimum inhibitory concentration; ARPA, antibiotics-resistant *Pseudomonas aeruginosa*; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; DCM, dichloromethane; DMF, *N,N*-dimethylformamide; Fmoc, fluorenylmethyloxycarbonyl; HOBt, 1-hydroxybenzotriazole; DIC, 1,3-diisopropylcarbodiimide; TFA, trifluoroacetic acid; CLSI, clinical and laboratory standards institute; ITO, indium tin oxide

* Corresponding author. Tel.: +82 53 950 5373; fax: +82 53 955 5522.

E-mail address: dglee222@knu.ac.kr (D.G. Lee).

2. Materials and methods

2.1. Solid-phase peptide synthesis

Anygen Co. (Gwangju, Korea) carried out the peptide synthesis. Anygen Co. offers the following procedures for peptide synthesis. The assembly of peptides consisted of a 60-min cycle for each residue at ambient temperature as follows: (1) the 2-chlorotrityl (or 4-methylbenzhydrylamine amide) resin was charged to a reactor and then washed with DCM and DMF, respectively, and (2) a coupling step with vigorous shaking using a 0.14 mM solution of Fmoc-L-amino acids and Fmoc-L-amino acids preactivated for approximately 60 min with a 0.1 mM solution of 0.5 M HOBt/DIC in DMF. Finally, the peptide was cleaved from the resin using a TFA cocktail solution at ambient temperature [18,19].

2.2. Peptide characterization

Analytical and preparative reverse-phase HPLC runs were performed with a Shimadzu 20 A or 6 A gradient system. Data was collected using an SPD-20 A detector at 230 nm. Chromatographic separations were achieved with a 1%/min linear gradient of buffer B in A (A = 0.1% TFA in H₂O; B = 0.1% TFA in acetonitrile (CH₃CN)) over 40 min at flow rates of 1 and 8 ml/min using Shimadzu C₁₈ analytical (5 μm, 0.46 cm × 25 cm) and preparative C₁₈ (10 μm, 2.5 cm × 25 cm) columns, respectively. The HPLC retention time (min) of Rev-NIS, Anal R, and Anal S is 18.992, 13.550, and 15.433, respectively. The mass spectrometry was also performed. The observed mass of Rev-NIS, Anal R, and Anal S is 1183.2, 1251.9, and 1155.8, respectively.

2.3. CD analysis

CD spectra of the peptides were recorded using a spectropolarimeter (Jasco J720; Japan). All samples were maintained at 25 °C during the analysis. Four scans per sample were performed over a wavelength range of 190–250 nm at 0.1 nm intervals. The spectra were measured in 50% (v/v) TFE and 30 mM SDS in 10 mM sodium phosphate buffer, pH 7.2, respectively, at 25 °C using a 1-mm path-length cell. The peptide concentrations were 50 μM. The mean residue ellipticity, $[\theta]$, is given in deg·cm²·dmol⁻¹: $[\theta] = [\theta]_{\text{obs}} (\text{MRW}/10l)$, where $[\theta]_{\text{obs}}$ is the ellipticity measured in millidegrees, MRW is the mean residue molecular weight of the peptide, c is the concentration of the sample in mg/ml, and l is the optical path-length of the cell in cm [20,21].

2.4. Isolation of bacterial strains and determining of antibacterial susceptibility

All bacterial strains were isolated from a tertiary teaching hospital in Daegu, South Korea. All isolates were processed by the MicroScan WalkAway 96 system for genus and species identification and the determination of the antimicrobial susceptibility testing. MicroScan Gram positive MIC/combo (PC1A) panel, Gram negative MIC/combo (NC44) panel, and Gram negative breakpoint combo (NBC39) panel were used in determining antimicrobial agent susceptibility and identification to the species level of *Enterococcus faecium*, *Staphylococcus aureus*, *Escherichia coli*, and *Pseudomonas aeruginosa*, respectively.

Inoculum suspensions for the system were processed on the same day using the same fresh 18- to 24-h subculture plate. The Prompt Inoculation System-D was used to standardize inocula for microdilution antimicrobial susceptibility tests. All procedures were performed according to the manufacturers' recommendations. All antimicrobial susceptibility tests were performed in compliance with current CLSI methods as recommended by the manufacturers' package inserts with the products. Quality control was monitored by using the following

organisms: *S. aureus* ATCC 29213, *P. aeruginosa* ATCC 27853, and *E. coli* ATCC 25922.

2.5. Antibacterial susceptibility testing

Bacterial cells (2×10^7 /ml) were inoculated into a Mueller-Hinton broth and 0.1 ml/well was dispensed onto 96-well microtiter plates. The bacterial numbers were calculated by measurement of turbidity with a spectrophotometer (DU530; Beckman, Fullerton, CA, U.S.A.). MICs were determined by a serial two-fold dilution of test peptides, following the recommendations of the Clinical and Laboratory Standards Institute (CLSI). After 24 h of incubation at 37 °C, the minimal peptide concentration required to prevent the growth of a given test organism was determined and was defined as the MIC. The growth was assayed with a microtiter ELISA Reader (Molecular Devices Emax, CA, U.S.A.) by monitoring absorption at 620 nm [22].

2.6. Hemolytic activity assay

The hemolytic activity of the peptides was evaluated by measuring the absorbance at 414 nm with an ELISA Reader to determine the release of hemoglobin from a 4% suspension of human erythrocytes [17]. The hemolysis percentage was calculated using the following equation: %Hemolysis = $100[(\text{Abs}_{414 \text{ nm}} \text{ in the peptide solution} - \text{Abs}_{414 \text{ nm}} \text{ in PBS}) / (\text{Abs}_{414 \text{ nm}} \text{ in 0.1\% Triton X-100} - \text{Abs}_{414 \text{ nm}} \text{ in PBS})]$.

2.7. Membrane depolarization assay

Measurements of cytoplasmic membrane depolarization were made using a membrane potential-sensitive probe, diSC₃5. DiSC₃5 was purchased from Sigma Chemical Co. (USA). *E. coli* O-157 cells were grown at 37 °C to mid-log phase, centrifuged (3500 rpm, 7 min) and washed with 5 mM HEPES buffer (pH 7.2) containing 20 mM glucose and resuspended in buffer (5 mM HEPES buffer, 20 mM glucose, 100 mM KCl, pH 7.2) to an OD₆₀₀ of 0.05. Changes in fluorescence due to the collapse of the cytoplasmic membrane potential were continuously monitored at 20 °C using a Shimadzu RF-5301 spectrofluorophotometer at an excitation wavelength of 622 nm and an emission wavelength of 670 nm. When the dye uptake was maximal, as indicated by a stable reduction in fluorescence due to quenching of the accumulated dye in the membrane interior, peptides (at the MIC) were added to the cells. Measurements were repeated two times under each condition to ensure reproducibility [23].

2.8. Preparation of FD-loaded liposome and leakage assay

FITC-labeled dextrans (FD4, FD10, and FD20) were employed to evaluate the extent of membrane damage induced by the peptides. All FDs were purchased from Sigma Chemical Co. (USA). To prepare FD-entrapped liposome, buffer I (1 ml, 50 mM potassium phosphate, pH 7.4, with 0.1 mM EDTA) containing 2 mg/ml of FD, was sonicated for 30 min with 20 mg/ml of lipid [PE/PG (7:3, w/w)] solution in chloroform on ice. Chloroform was removed by using a rotary vacuum evaporator for 2 h at 25 °C, resulting first in the formation of a viscous gel, and then a liposome suspension. Buffer I (2 ml) was added and the suspension was evaporated further for the removal of eventual traces of chloroform. The liposome suspension was sonicated, centrifuged and washed for several cycles at 13,000 rpm for 30 min to remove untrapped-FD. For the assay, the peptides (at the MIC) were treated in a suspension of FD-loaded liposome. The mixture (3 ml, final volume) was stirred for 10 min in the dark and then centrifuged at 13,000 rpm for 20 min. The supernatant was recovered and its fluorescence intensity was recorded by measuring a fluorescent intensity, at wavelengths ($\lambda_{\text{ex}} = 494 \text{ nm}$, $\lambda_{\text{em}} = 520 \text{ nm}$), with RF-5301PC spectrofluorophotometer (Shimadzu, Japan). 20 μl of 10%




Fig. 3. Effects of melittin, Rev-NIS, and its analogs on the membrane potential of intact *E. coli* O-157 cells ($OD_{600} = 0.05$). DiSC₃₅ fluorescence was measured as described in **Materials and methods**. The peptides were treated at the MIC value. (A) Cells treated with melittin. (B) Cells treated with Rev-NIS. (C) Cells treated with Anal R. (D) Cells treated with Anal S.

summary, the peptides including Rev-NIS are expected to overcome the resistance of bacteria, and they can be one of the most promising potential next generation antibiotic models.

The amphipathic property can induce the effective interactions of the peptides with the cell plasma membranes, consisting of phospholipids. Thus, a representative characteristic, observed for membrane-active peptides, is their disruptive action toward bilayer

integrity, like depolarization and pore formation. This action on the membranes can often lead to the collapse of the transmembrane electrochemical gradients and, consequently, provide a description regarding the cell killing activities [44,45]. The pore formation affects cellular respiration [46], deprives organisms of an energy source by disrupting the electrochemical gradient, across free-energy transduction within the membranes [47,48]. Lastly, this process results in cell swelling and osmolysis, due to the flow of ion or water [27,49].

In the previous study, Rev-NIS showed the antifungal activity via the membrane-disruptive action against *C. albicans*. To examine that Rev-NIS also showed antibacterial effects by a similar mode of action, we first performed diSC₃₅ assay using *E. coli* O-157. This dye is a membrane potential-sensitive fluorescent probe [50]. If it crosses the outer membrane, diSC₃₅ can be taken up by the cells, according to the magnitude of the electrical potential gradient of the cytoplasmic membrane, and thereafter, it accumulates in the membrane, where it self-quenches its own fluorescence. Providing that the peptides disrupt the cytoplasmic membrane and that this action results in the depolarization of the $\Delta\Psi$, the electrical potential gradient, we can check the release of diSC₃₅ through the increase of fluorescence [51]. The result indicated that all the peptides remarkably disrupted the cytoplasmic membrane of *E. coli* O-157 and that the pattern of potency was consistent with the result of MIC assay (Anal R > Rev-NIS > Anal S). It further suggests that the substituted positively charged arginine (R) is very significant in the interaction between the peptide and the negatively charged LPS, PE or PG of the *E. coli* O-157. Regarding PE, in *E. coli* cells, the fluorescence signal of Ro (Ro09-0198)-bound PE is uniformly distributed in the cell surface, and this observation indicates that PE is uniformly localized over the whole bacterial cell membrane [52]. Ro is the cyclic peptide probe that can bind specifically to PE [53]. Moreover, it was thought that the decreased hydrophobicity, by substituting serine (S), weakened the hydrophobic interactions between the hydrophobic residues of Rev-NIS and the




Fig. 4. Percentage of FITC-dextran (FD) leakage induced by melittin, Rev-NIS, and its analogs from PE/PG [7:3 (w/w)] liposome. The peptides were treated at the MIC value. The error bars represent the standard deviation values for three independent experiments, performed in triplicate.

hydrophobic tail region of the bacterial membranes, after the interactions of the positively charged amino acids, such as K⁴, R⁷, and K¹⁰, with the negatively charged components. When considering the pattern of hydrophobicity, this fact supported that the net positive charge is one of the most crucial factors.

To confirm the mode of action of the peptides, the FD leakage assay was conducted. This assay, using FDs of both the different molecular weight and the radius, is a method to elucidate the pore-forming mechanism in the membrane perturbation process [54,55]. The radius of Rev-NIS and its analogs-induced pores may be anywhere from 1.4 nm to 2.3 nm. Also, the radius of pores induced by Anal R is considered to be from 2.3 nm to 3.3 nm. This result indicated that the substituting with two arginines increased the net positive charge of the peptide, and thereafter, the increased positive charge makes the interaction between the peptide and the negative charged components more potent. It meant that the high affinity regarding the interaction between the positively charged residues of Anal R induced larger pores than other peptides. In conclusion, these results suggest that the peptides in this study make pores in the bacterial cell membranes, can affect cellular respiration, and cause the membrane to transport water or ions. Finally, the peptides can be thought to cause the bacterial cell death. Considering that the negatively charged phospholipids are uniformly distributed in both the outer and the inner membranes of bacteria, as compared with those of fungi and mammals, specifically, Anal R possessing many arginines is thought to be a potent candidate as a novel antibacterial agent.

Our ultimate goals have been to develop and suggest novel non-toxic antibiotic peptides with noticeable potency and range of susceptible microorganisms to be of practical utility. The pore forming peptides studied herein, Rev-NIS and its analogs, Anal R, and Anal S, were conducive with the conditions mentioned above, and among the peptides, Anal R can be a novel potential antibiotic itself or a template for designing new therapeutic agents.

Acknowledgments

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No. 2011-0000915).

References

- [1] F.M. MacKenzie, M.J. Struelens, K.J. Townner, I.M. Gould, Report of the Consensus Conference on Antibiotic Resistance; Prevention and Control (ARPAC), Clin. Microbiol. Infect. 11 (2005) 938–954.
- [2] J.T. Weber, P. Courvalin, An emptying quiver: antimicrobial drugs and resistance, Emerg. Infect. Dis. 11 (2005) 791–793.
- [3] B. Cookson, Clinical significance of emergence of bacterial antimicrobial resistance in the hospital environment, J. Appl. Microbiol. 99 (2005) 989–996.
- [4] K.L. Roos, Emerging antimicrobial-resistant infection, Arch. Neurol. 61 (2004) 1512–1514.
- [5] D.L. Paterson, The epidemiological profile of infections with multidrug-resistant *Pseudomonas aeruginosa* and *Acinetobacter* species, Clin. Infect. Dis. 43 (Suppl. 2) (2006) S43–S48.
- [6] L.B. Rice, Antimicrobial resistance in Gram-positive bacteria, Am. J. Infect. Control 34 (5 Suppl. 1) (2006) S11–S19.
- [7] D.G. White, S. Zhao, S. Simjee, D.D. Wagner, P.F. McDermott, Antimicrobial resistance of foodborne pathogens, Microbes Infect. 4 (2002) 405–412.
- [8] K. Lohner, Development of Novel Antimicrobial Agents: Emerging Strategies, Horizon Scientific Press, Wymondham, Norfolk, UK, 2001.
- [9] R. Novak, B. Henriques, E. Charpentier, S. Normark, E. Tuomanen, Emergence of vancomycin tolerance in *Streptococcus pneumoniae*, Nature 399 (1999) 590–593.
- [10] B. Bechinger, K. Lohner, Detergent-like actions of linear amphipathic cationic antimicrobial peptides, Biochim. Biophys. Acta 1758 (2006) 1529–1539.
- [11] M. Zasloff, Antimicrobial peptides of multicellular organisms, Nature 415 (2002) 389–395.
- [12] K.H. Kalland, A.M. Szilvay, K.A. Brokstad, W. Saetrevik, G. Haukenes, The human immunodeficiency virus type 1 Rev protein shuttles between the cytoplasm and nuclear compartments, Mol. Cell. Biol. 14 (1994) 7436–7444.
- [13] B.E. Meyer, M.H. Malim, The HIV-1 Rev trans-activator shuttles between the nucleus and the cytoplasm, Genes Dev. 8 (1994) 1538–1547.
- [14] N. Richard, S. Iacampo, A. Cochrane, HIV-1 Rev is capable of shuttling between the nucleus and cytoplasm, Virology 204 (1994) 123–131.
- [15] B. Wolff, G. Cohen, J. Hauber, D. Meshcheryakova, C. Rabeck, Nucleocytoplasmic transport of the Rev protein of human immunodeficiency virus type 1 is dependent on the activation domain of the protein, Exp. Cell Res. 217 (1995) 31–41.
- [16] S. Kubota, R.J. Pomerantz, A cis-acting peptide signal in human immunodeficiency virus type 1 Rev which inhibits nuclear entry of small proteins, Oncogene 16 (1998) 1851–1861.
- [17] J. Lee, D.G. Lee, Antifungal properties of a peptide derived from the signal peptide of the HIV-1 regulatory protein, Rev, FEBS Lett. 583 (2009) 1544–1547.
- [18] B. Merrifield, Solid phase synthesis, Science 232 (1986) 341–347.
- [19] R. Sheppard, The fluorenylmethoxycarbonyl group in solid phase synthesis, J. Pept. Sci. 9 (2003) 545–552.
- [20] J. Lee, D.G. Lee, Structure–antimicrobial activity relationship between pleurocidin and its enantiomer, Exp. Mol. Med. 40 (2008) 370–376.
- [21] M.K. Lee, H.K. Kim, T.Y. Lee, K.S. Hahm, K.L. Kim, Structure–activity relationships of anti-HIV-1 peptides with disulfide linkage between D- and L-cysteine at positions i and i + 3, respectively, derived from HIV-1 gp41 C-peptide, Exp. Mol. Med. 38 (2006) 18–26.
- [22] J. Lee, Y. Choi, E.R. Woo, D.G. Lee, Antibacterial and synergistic activity of isocryptomerin isolated from *Selaginella tamariscina*, J. Microbiol. Biotechnol. 19 (2009) 204–207.
- [23] S.T. Yang, S.Y. Shin, K.S. Hahm, J.J. Kim, Different modes in antibiotic action of tritriptin analogs, cathelicidin-derived Trp-rich and Pro/Arg-rich peptides, Biochim. Biophys. Acta 1758 (2006) 1580–1586.
- [24] O.S. Belokoneva, H. Satake, E.L. Mal'tseva, N.P. Pal'mina, E. Villegas, T. Nakajima, G. Corzo, Pore formation of phospholipid membranes by the action of two hemolytic arachnid peptides of different size, Biochim. Biophys. Acta 1664 (2004) 182–188.
- [25] S.C. Park, M.H. Kim, M.A. Hossain, S.Y. Shin, Y. Kim, L. Stella, J.D. Wade, Y. Park, K.S. Hahm, Amphipathic alpha-helical peptide, HP (2–20), and its analogues derived from *Helicobacter pylori*: pore formation mechanism in various lipid compositions, Biochim. Biophys. Acta 1778 (2008) 229–241.
- [26] E. Habermann, Bee and wasp venoms, Science 177 (1972) 314–322.
- [27] M.T. Tosteson, S.J. Holmes, M. Razin, D.C. Tosteson, Melittin lysis of red cells, J. Membr. Biol. 87 (1985) 35–44.
- [28] C.E. Dempsey, The actions of melittin on membranes, Biochim. Biophys. Acta 1031 (1990) 143–161.
- [29] Y. Kamio, Y. Saito, N. Utoguchi, M. Kondoh, N. Koizumi, M. Fujii, Y. Watanabe, Epinephrine is an enhancer of rat intestinal absorption, J. Control. Release 102 (2005) 563–568.
- [30] K.V. Reddy, R.D. Yedery, C. Aranha, Antimicrobial peptides: premises and promises, Int. J. Antimicrob. Agents 24 (2004) 536–547.
- [31] S.J. Arrigo, I.S. Chen, Rev is necessary for translation but not cytoplasmic accumulation of HIV-1 vif, vpr, and env/vpu 2 RNAs, Genes Dev. 5 (1991) 808–819.
- [32] D.M. D'Agostino, B.K. Felber, J.E. Harrison, G.N. Pavlakis, The Rev protein of human immunodeficiency virus type 1 promotes polysomal association and translation of gag/pol and vpu/env mRNAs, Mol. Cell. Biol. 12 (1992) 1375–1386.
- [33] U. Fischer, S. Meyer, M. Teufel, C. Heckel, R. Lührmann, G. Rautmann, Evidence that HIV-1 Rev directly promotes the nuclear export of unspliced RNA, EMBO J. 13 (1994) 4105–4112.
- [34] M.H. Malim, J. Hauber, S.Y. Le, J.V. Maizel, B.R. Cullen, The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA, Nature 338 (1989) 254–257.
- [35] S. Heaphy, J.T. Finch, M.J. Gait, J. Karn, M. Singh, Human immunodeficiency virus type 1 regulator of virion expression, rev, forms nucleoprotein filaments after binding to a purine-rich “bubble” located within the rev-responsive region of viral mRNAs, Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 7366–7370.
- [36] M.H. Malim, B.R. Cullen, HIV-1 structural gene expression requires the binding of multiple Rev monomers to the viral RRE: implications for HIV-1 latency, Cell 65 (1991) 241–248.
- [37] M.L. Zapp, M.R. Green, Sequence-specific RNA binding by the HIV-1 Rev protein, Nature 342 (1989) 714–716.
- [38] S. Kubota, H. Siomi, T. Satoh, S. Endo, M. Maki, M. Hatanaka, Functional similarity of HIV-1 rev and HTLV-1 rex proteins: identification of a new nucleolar-targeting signal in rev protein, Biochem. Biophys. Res. Commun. 162 (1989) 963–970.
- [39] U. Fischer, J. Huber, W.C. Boelens, I.W. Mattaj, R. Lührmann, The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs, Cell 82 (1995) 475–483.
- [40] W.M. Michael, M. Choi, G. Dreyfuss, A nuclear export signal in hnRNP A1: a signal-mediated, temperature-dependent nuclear protein export pathway, Cell 83 (1995) 415–422.
- [41] W. Wen, J.L. Meinkoth, R.Y. Tsien, S.S. Taylor, Identification of a signal for rapid export of proteins from the nucleus, Cell 82 (1995) 463–473.
- [42] E. Walter, T. Kissel, G.L. Amidon, The intestinal peptide carrier: a potential transport system for small peptide derived drugs, Adv. Drug Deliv. Rev. 20 (1996) 33–58.
- [43] D.M. Matthews, J.W. Payne, Transmembrane transport of small peptides, Curr. Top. Membr. 14 (1980) 331–425.
- [44] B. Bechinger, The structure, dynamics and orientation of antimicrobial peptides in membranes by multidimensional solid-state NMR spectroscopy, Biochim. Biophys. Acta 1462 (1999) 157–183.
- [45] Y. Shai, Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides, Biochim. Biophys. Acta 1462 (1999) 55–70.

- [46] M. Hugosson, D. Andreu, H.G. Boman, E. Glaser, Antibacterial peptides and mitochondrial presequences affect mitochondrial coupling, respiration and protein import, *Eur. J. Biochem.* 223 (1994) 1027–1033.
- [47] H.V. Westerhoff, D. Juretić, R.W. Hendler, M. Zasloff, Magainins and the disruption of membrane-linked free-energy transduction, *Proc. Natl. Acad. Sci. U.S.A.* 86 (1989) 6597–6601.
- [48] L. Silvestro, K. Gupta, J.N. Weiser, P.H. Axelsen, The concentration-dependent membrane activity of cecropin A, *Biochemistry* 36 (1997) 11452–11460.
- [49] W.F. DeGrado, G.F. Musso, M. Lieber, E.T. Kaiser, F.J. Kézdy, Kinetics and mechanism of hemolysis induced by melittin and by a synthetic melittin analogue, *Biophys. J.* 37 (1982) 329–338.
- [50] P.J. Sims, A.S. Waggoner, C.H. Wang, J.F. Hoffman, Studies on the mechanism by which cyanine dyes measure membrane potential in red blood cells and phosphatidylcholine vesicles, *Biochemistry* 13 (1974) 3315–3330.
- [51] L. Zhang, P. Dhillon, H. Yan, S. Farmer, R.E. Hancock, Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of *Pseudomonas aeruginosa*, *Antimicrob. Agents Chemother.* 44 (2000) 3317–3321.
- [52] A. Nishibori, J. Kusaka, H. Hara, M. Umeda, K. Matsumoto, Phosphatidylethanolamine domains and localization of phospholipid synthases in *Bacillus subtilis* membranes, *J. Bacteriol.* 187 (2005) 2163–2174.
- [53] K. Emoto, M. Umeda, Membrane lipid control of cytokinesis, *Cell Struct. Funct.* 26 (2001) 659–665.
- [54] J.M. Mancheño, M. Oñaderra, A. Martínez del Pozo, P. Díaz-Achirica, D. Andreu, L. Rivas, J.C. Gavilanes, Release of lipid vesicle contents by an antibacterial cecropin A-melittin hybrid peptide, *Biochemistry* 35 (1996) 9892–9899.
- [55] S. Rex, Pore formation induced by the peptide melittin in different lipid vesicle membranes, *Biophys. Chem.* 58 (1996) 75–85.